FCCC LOGO Faculty Publications
Konski A
Cost-effectiveness of intensity-modulated radiation therapy
Expert Review of Pharmacoeconomics and Outcomes Research. 2005 ;5(2) :137-140
Back to previous list
Abstract
Technical advances have given medicine the opportunity to refine current treatment techniques to improve outcomes. Computed tomography, magnetic resonance imaging and high energy linear accelerators are but a few examples of technology translating into clinical practice. Intensity-modulated radiation therapy is a form of 3D conformal radiation that is being increasingly incorporated into the management of patients with prostate cancer. As with any new technology, the cost of intensity-modulated radiation therapy is considerably greater than standard therapy. Economic models can be useful to compare treatments when this comparison cannot be performed in a clinical trial. A Markov Model was used to compare the use of intensity-modulated radiation with 3D conformal radiation therapy in the treatment of a 70 year old man with a good- and intermediate-risk prostate cancer. Cost data for men with Medicare insurance and prostate cancer treated with intensity-modulated radiation therapy and 3D conformal radiation therapy was obtained from the billing department at the Fox Chase Cancer Center (PA, USA). Utilities were collected from men undergoing intensity-modulated radiation therapy and 3D conformal radiation therapy for prostate cancer. Intensity-modulated radiation therapy was found to be cost effective in the treatment of a 70 year old man with prostate cancer with a incremental cost-effectiveness ratio of US$ 16,182 /quality-adjusted life year for men with intermediate-risk prostate cancer and US$ 17,448/ quality-adjusted life year for men with good-risk prostate cancer. Sensitivity analysis found that a longer time horizon of the analysis and younger age at treatment favorably impact the cost-effectiveness ratio. © 2005 Future Drugs Ltd.
Notes
14737167 (ISSN) Cited By: 0; Export Date: 25 May 2006; Source: Scopus CODEN: ERPOB; DOI: 10.1586/14737167.5.2.137 Language of Original Document: English Correspondence Address: Konski, A.; Department of Radiation Oncology; Fox Chase Cancer Center; 333 Cottman Ave. Philadelphia, PA 19111, United States; email: andre.konski@fccc.edu References: Young, R., Snyder, B., IMRT (intensity modulated radiation therapy): Progress in technology and reimbursement (2001) Radiol. Manage., 23 (6), pp. 20-26; Zelefsky, M.J., Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer (1998) Int. J. Radiat. Oncol. Biol. Phys., 41 (3), pp. 491-500; Zelefsky, M.J., High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients (2002) Int. J. Radiat. Oncol. Biol. Phys., 53 (5), pp. 1111-1116; Fleming, C., A decision analysis of alternative treatment strategies for clinically localized prostate cancer (1993) JAMA, 269 (20), pp. 2650-2658, Prostate Patient Outcomes Research Team; Hanks, G.E., Dose response in prostate cancer with 8-12 years' follow-up (2002) Int. J. Radiat. Oncol. Biol. Phys., 54 (2), pp. 427-435; Chism, D.B., Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement (2003) Int. J. Radiat. Oncol. Biol. Phys., 55 (1), pp. 71-77; Oefelein, M.G., Agarwal, P.K., Resnick, M.I., Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era (2004) J. Urol., 171 (4), pp. 1525-1528; Scher, H.I., Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer (1999) J. Natl. Cancer Inst., 91 (3), pp. 244-251; Consensus statement: Guidelines for PSA following radiation therapy (1997) Int. J. Radiat. Oncol. Biol. Phys., 37, pp. 1035-1041, American Society for Therapeutic Radiology and Oncology Consensus Panel; Kuntz, M.C., Modelling in economic evaluation (2001) Economic Evaluation in Health Care, Drummond A (Ed.). Oxford University Press, Oxford, UK; Briggs, A.H., Handling uncertainty in economic evaluation and presenting the results (2001) Economic Evaluation in Health Care, Drummond A (Ed.). Oxford University Press, Oxford, UK; Piper, N.Y., Adenocarcinoma of the prostate: An expensive way to die (2002) Prostate Cancer Prostatic Dis., 5 (2), pp. 164-166; Doubilet, P., Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach (1985) Med. Dec. Making, 5 (2), pp. 157-177; EuroQol - A new facility for the measurement of health-related quality of life (1990) Health Pol., 16, pp. 199-208, The EuroQol Group; Hummel, S., Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: A systematic review (2003) Health Technol. Assess., 7 (33), pp. 1-157.